BOSTON and DURHAM, N.C., June 4, 2013 /PRNewswire/ -- Riverside Partners, a Boston-based
private equity firm, is pleased to announce that it has completed an
investment in BioAgilytix Labs ("BioAgilytix"), a leading contract
bioanalytical laboratory specializing in large molecule biologic drugs.
Riverside Partners' investment was completed in partnership with the
BioAgilytix Founders and management team.
Headquartered in Research Triangle Park, North Carolina,
BioAgilytix provides outsourced laboratory services to customers within
the pharmaceutical, biotechnology, and agriculture industries. By
developing, optimizing and conducting bioanalytic testing, the Company
offers its customers a high-quality outsourcing option, which supports
drug discovery, pre-clinical and clinical development, and
manufacturing.
"The BioAgilytix team is very excited work with Riverside Partners. The Riverside
team has a great understanding of how to scale a pharmaceutical
services business, and the two organizations have a very strong cultural
fit," said Jim Petrilla , Co-Founder and CEO of BioAgilytix.
"Co-Founders Jim Petrilla and Dr. Afshin Safavi
have built a terrific business focused on supporting large molecule
drug development, a very exciting area within the pharmaceutical and
biotechnology industries. Riverside Partners is looking forward to
utilizing our deep healthcare experience to help accelerate the
Company's growth," said Philip Borden , General Partner at Riverside Partners.
About BioAgilytix Labs
BioAgilytix
Labs is a specialized bioanalytical testing laboratory focused on large
molecule bioanalysis for the pharmaceutical, biotechnology and
agriculture industries. BioAgilytix Lab's mission is to provide
outsourced analysis of biological samples that supports the work of
companies seeking regulatory approval of their biopharmaceutical and
agricultural products. For more information on the Company, please visit
www.bioagilytix.com.
About Riverside Partners
Founded
in 1989, Riverside Partners is a middle market private equity firm
currently investing Riverside Partners Fund V, L.P. The fund focuses on
growth-oriented companies primarily in the healthcare and technology
industries. Riverside Partners is particularly experienced at
partnering with founders, owners and management teams and it brings
substantial domain expertise and operating experience to its portfolio
companies. Today, Riverside Partners manages $1 billion of equity capital and seeks to make investments in companies with revenues between $20 and $200 million and with $5-$25 million of EBITDA.
For more information, please visit
Copyright 2009, Riverside Partners, LLC.
SOURCE Riverside Partners
RELATED LINKS
http://www.riversidepartners.com
No comments:
Post a Comment